Literature DB >> 2887941

Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication.

D H Roberts, Y Tsao, G A McLoughlin, A Breckenridge.   

Abstract

In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month. Although all treatments were equally effective at lowering blood pressure, pain-free and maximum walking distances on a treadmill were decreased by atenolol, labetalol, and pindolol, but not by captopril. Post-exercise calf blood flow availability was impaired by atenolol, labetalol, and pindolol, but not by captopril. Despite ancillary characteristics of cardioselectivity, intrinsic sympathomimetic activity, or combination with alpha-blockade, beta-blockers seem to impair the lower limb circulation in such patients, whereas captopril seems to preserve it, possibly by maintaining the collateral blood supply.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887941     DOI: 10.1016/s0140-6736(87)92441-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Current strategies in the diagnosis and management of lower extremity peripheral vascular disease.

Authors:  T J Wilt
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

2.  Unsuspected renal artery stenosis in peripheral vascular disease.

Authors:  A H Choudhri; J G Cleland; P C Rowlands; T L Tran; M McCarty; M A al-Kutoubi
Journal:  BMJ       Date:  1990-11-24

Review 3.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 4.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 5.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Treating claudication in five words.

Authors:  E Housley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-28

Review 7.  Perindopril safety and tolerance in at-risk patients.

Authors:  S Brichard; A E Lambert
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 8.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 9.  Role of ACE inhibitors in hypertension complicated by vascular disease.

Authors:  G T McInnes
Journal:  Br Heart J       Date:  1994-09

10.  The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle.

Authors:  Jessica Chinsomboon; Jorge Ruas; Rana K Gupta; Robyn Thom; Jonathan Shoag; Glenn C Rowe; Naoki Sawada; Srilatha Raghuram; Zoltan Arany
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.